Research groups
Colleges
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Recent publications
-
Is It Possible to Screen for Primary Aldosteronism Effectively in Primary Care?
Dissanayake HA. et al, (2025), Clin Endocrinol (Oxf)
-
Pregnancy Outcomes in Women With Primary Adrenal Insufficiency: Data From a Multicentre Cohort Study.
Cauldwell M. et al, (2025), BJOG
-
Prevalence and management of hypertension in Turner syndrome: data from the International Turner Syndrome (I-TS) registry.
Mathara Diddhenipothage SAD. et al, (2025), Endocr Connect, 14
-
Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
Moolla A. et al, (2025), JHEP Reports, 101363 - 101363
-
Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Golubic R. et al, (2024), Diabet Med